Morepen Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 30-Aug-2025.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.9 pts less than Nifty Microcap 250 and 5.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited Q1 FY26 results (quarter ended June 30, 2025) and set August 30, 2025 as the record date for the final dividend, pending AGM approval. Consolidated total income fell to Rs. 42,964.73 lakhs from Rs. 45,864.27 lakhs year-on-year, while net profit after minority interest dropped sharply to Rs. 1,074.83 lakhs from Rs. 3,616.79 lakhs — a decline of about 70%. Standalone net profit fell even more steeply to Rs. 806.12 lakhs from Rs. 3,504.96 lakhs. The board also approved hiving off the Medical Devices Business into subsidiary Morepen Medipath Limited on a slump sale basis, subject to shareholder approval. Separately, the company's stake in Dr. Morepen Limited has come down from 80% to 19.94%, meaning it will no longer be treated as a subsidiary. Mr. Sanjay Suri was re-appointed as Whole-Time Director for three years and a new Secretarial Auditor was appointed for five years.
The steep year-on-year fall in profits on both standalone and consolidated bases is a red flag for investors, though the dividend record date signals continued shareholder returns. The de-subsidiarization of Dr. Morepen Limited and the proposed hive-off of the Medical Devices Business will change the structure of future consolidated results, so investors should watch for how these moves affect earnings and business focus going into the September 6 AGM.